NCT05399654
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05399654
Title A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors (INCLINE-101)
Acronym INCLINE-101
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Tallac Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
University of Southern California (USC) Los Angeles California 90033 United States Details
University of Colorado Aurora Colorado 80045 United States Details
Sarah Cannon Research Institute (SCRI)- Denver Denver Colorado 80218 United States Details
AdventHealth Cancer Institute Orlando Florida 32804 United States Details
Sarah Cannon Research Institute (SCRI)- Florida Cancer Specialists and Research Institute, LLC Orlando Florida 32827 United States Details
John Theurer Cancer Center Hackensack New Jersey 07601 United States Details
Weill Cornell Medicine- NYU Clinical Cancer Center New York New York 10065 United States Details
West Cancer Center & Research Institute Germantown Tennessee 38138 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
NEXT Oncology Irving Texas 75039 United States Details
NEXT Oncology- Virginia Fairfax Virginia 22031 United States Details
Clinical Site Nedlands Western Australia 6009 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field